Centrexion analgesic shows durable effect in Phase IIb

Centrexion Therapeutics Corp. (Boston, Mass.) said a single injection of CNTX-4975 led to a durable effect in the Phase IIb TRIUMPH trial to treat moderate to severe knee pain associated with osteoarthritis (OA). New data showed that the therapy, which had already met the study's 12-week primary endpoint, also significantly reduced daily walking pain from baseline to 24 weeks vs. placebo.

The company plans to start a Phase III trial this year. For that study's primary endpoint, Centrexion intends to evaluate change in pain with walking after 12 weeks of treatment vs. placebo...